Highly Specialised Drugs

Exported from METEOR (AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY4.0 (CC BY4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at https://creativecommons.org/licenses/by/4.0/.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

Highly Specialised Drugs

Identifying and definitional attributes

Metadata item type:	Glossary Item
Synonymous names:	HSDs
METEOR identifier:	623382
Registration status:	Commonwealth Department of Health, Retired 19/10/2023
Definition:	Highly Specialised Drugs (HSDs) are medicines for the treatment of chronic conditions which, prior to 1 July 2015, were restricted to supply through public and private hospitals having access to appropriate specialist facilities because of their clinical use or other special features.
	To prescribe these drugs as pharmaceutical benefit items, medical practitioners were required to be affiliated with these specialist hospital units. A general practitioner or non-specialist hospital doctor could only prescribe Highly Specialised Drugs to provide maintenance therapy under the guidance of the treating specialist.
	A small number of drugs included in the HSD program became available via community pharmacies from 1 July 2015.
	HSDs are subsidised through the Pharmaceutical Benefits Scheme (PBS) and administered under Section 100 of the <i>National Health Act</i> 1953 (Cwth).
Context:	Pharmaceutical Benefits Scheme (PBS).

Collection and usage attributes

Guide for use: From 1 July 2015, a limited number of Highly Specialised Drugs, e.g. clozapine for the treatment of schizophrenia (maintenance therapy only), HIV antiretroviral medicines and hepatitis B medicines, became available via community pharmacies, thereby removing the requirement for some patients and prescribers to be affiliated with a hospital setting.

Source and reference attributes

Steward:	Department of Health and Aged Care
Reference documents:	Office of Parliamentary Counsel, ComLaw website 2014. National Health Act 1953 (Cwth). Office of Parliamentary Counsel, Canberra. Viewed 22 September 2015, https://www.comlaw.gov.au/Details/C2015C00081
	Department of Health 2015. Section 100 – Highly Specialised Drugs Program web page. Department of Health, Canberra. Viewed 12 November 2015, http://www.pbs.gov.au/info/browse/section-100/s100-highly-specialised-drugs
	Department of Health 2015. Highly Specialised Drugs web page. Department of Human Services, Canberra. Viewed 12 November 2015, http://www.humanservices.gov.au/health-professionals/services/highly-specialised- drugs/

Relational attributes

Metadata items which use	Pharmaceutical Benefits Scheme (PBS) prescription drug broad category code
this glossary item:	XX
	Commonwealth Department of Health, Retired 19/10/2023
	Pharmacy approval type code X

<u>Pharmacy approval type code X</u> <u>Commonwealth Department of Health</u>, Retired 19/10/2023